Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 01) diffuse large B-cell lymphoma

Leukemia and Lymphoma

Volumn 50, Issue 11, 2009, Pages 1824-1829

  Derenzini, Enrico ^a   Stefoni, Vittorio ^a   Pellegrini, Cinzia ^a   Fina, Maria Paola ^a   Broccoli, Alessandro ^a   Venturini, Filippo ^a   Gandolfi, Letizia ^a   Pileri, Stefano A ^a   Martelli, Maurizio ^b   Petti, Maria Concetta ^c   Perrotti, Alessio ^d   De Renzo, Amalia ^e   Zaja, Francesco ^f   Baccarani, Michele ^a   Zinzani, Pier Luigi ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f UNIVERSITY OF UDINE   (Italy)

Author keywords

Chemotherapy; Diffuse large B cell lymphoma; IPI score; MACOP B; Rituximab

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; FEMALE; FOLLOW UP; HUMAN; INFECTION; LARGE CELL LYMPHOMA; LEUKOPENIA; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA; VOMITING;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; ITALY; LEUKOPENIA; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; METHOTREXATE; MIDDLE AGED; PREDNISONE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 71049194762     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903216796     Document Type: Article

References (17)

1. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non- Hodgkin's lymphoma. N Engl J Med 1993;339:987-994.
2. Pfreundschuh M, Zwick C, Zeynalova S, et al. Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: Results of the randomized high- CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2008;19:545-552.
3. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998;339:21-26.
4. Miller TP, Leblanc M, Spier C, et al. CHOP alone compared to CHOP plus radiotherapy for early stage non-Hodgkin's lymphomas: Update of the southwest oncology group (SWOG) randomized trial. Blood 2001;98:742a.
5. Horning SJ, Weller E, Kim K, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 2004;22:3032-3038.
6. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-Bcell lymphoma: A randomized controlled trial by the MabThera International Trial (MInt) Group. Lancet Oncol 2006;7:379-391.
7. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-3849.
8. Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 1985;102:596-602.
9. Cheson BD, Horning SJ, Coiffer B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244-1253.
10. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria formalignant lymphoma. J ClinOncol 2007;25:579-586.
11. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
12. Reyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 2005;352:1197-1205.
13. Tilly H, Lepage E, Coiffer B, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin's lymphoma. Blood 2003;102:4284-4289.
14. Verdonck LF, Notenboom A, De Jong DD, et al. Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP 21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: A phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). Blood 2007;109:2759-2766.
15. Cunningham D, Smith P, Mouncey P, et al. A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B-cell non- Hodgkin's lymphoma. J Clin Oncol 2009;27(Suppl):15s; abstr 8506.
16. Pfreundschuh M, Ho AD, Cavallin-Stahl E, et al. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: An exploratory analysis of the MabThera International Trial Group (MInt) study. Lancet Oncol 2008;9:435-444.
17. Zinzani PL, Stefoni V, Tani M, et al. MACOP-B Regimen followed by involved-field radiation therapy in early-stage aggressive non-Hodgkin's lymphoma patients: 14-year update results. Leuk Lymphoma 2001;42:989-995.